tiprankstipranks
Trending News
More News >
Harvard Apparatus Regenerative Technology (HRGN)
OTHER OTC:HRGN
US Market
Advertisement

Harvard Apparatus Regenerative Technology (HRGN) AI Stock Analysis

Compare
104 Followers

Top Page

HRGN

Harvard Apparatus Regenerative Technology

(OTC:HRGN)

Select Model
Select Model
Select Model
Underperform 37 (OpenAI - 4o)
Rating:37Underperform
Price Target:
HRGN faces significant financial challenges, with persistent net losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation is unattractive with a negative P/E ratio. The lack of positive earnings call updates contributes to a low overall stock score.

Harvard Apparatus Regenerative Technology (HRGN) vs. SPDR S&P 500 ETF (SPY)

Harvard Apparatus Regenerative Technology Business Overview & Revenue Model

Company DescriptionBiostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. It operates through Cellframe technology, engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. The company was founded on May 3, 2012 and is headquartered in Holliston, MA.
How the Company Makes MoneyHRGN makes money through the commercialization of its bioengineered organ products and regenerative medicine therapies. Revenue is generated from the sale of these products to healthcare providers, research institutions, and potentially through partnerships with other biotech firms. The company may also earn income through licensing agreements, where it licenses its technology to other companies for development or commercial use. Additionally, HRGN might receive funding or grants from government or private entities interested in advancing regenerative medicine technologies. Key revenue streams include product sales, licensing fees, and potentially milestone payments from collaborations or partnerships.

Harvard Apparatus Regenerative Technology Financial Statement Overview

Summary
Harvard Apparatus Regenerative Technology faces ongoing financial challenges. Despite some revenue growth, significant net losses and negative cash flows persist. Leverage is low, but the company struggles with negative equity. Profitability and cash flow issues need addressing for improved stability.
Income Statement
25
Negative
The company has demonstrated revenue growth from 2022 to 2023, with a 18.39% increase. However, it is still operating at a net loss, with a negative net profit margin of -8683.50%. Gross profit margin improved to 76.70% in 2023, but the EBIT and EBITDA margins remain significantly negative. Overall, the profitability metrics indicate significant challenges in achieving positive earnings.
Balance Sheet
35
Negative
The company's debt-to-equity ratio is relatively low, indicating manageable leverage. However, the equity ratio is 61.30%, showing reliance on equity financing. The return on equity is negative due to net losses, and the company has struggled with negative stockholders' equity in past years. These factors highlight ongoing financial instability.
Cash Flow
30
Negative
Free cash flow has deteriorated further from 2022 to 2023, declining by 35.97%. The operating cash flow to net income ratio is positive, suggesting better cash generation relative to net income losses, but the free cash flow to net income ratio remains negative, indicating cash flow challenges.
BreakdownDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue
Gross Profit79.00K87.00K
EBITDA-8.80M-6.20M-8.36M-4.69M-8.12M
Net Income-8.95M-6.07M-7.98M-4.87M-8.33M
Balance Sheet
Total Assets2.61M2.40M1.87M2.08M1.99M
Cash, Cash Equivalents and Short-Term Investments
Total Debt48.00K147.00K169.00K586.00K191.00K
Total Liabilities968.00K1.41M4.89M951.00K903.00K
Stockholders Equity
Cash Flow
Free Cash Flow-6.95M-5.11M-2.63M-4.05M-6.19M
Operating Cash Flow-6.94M-5.11M-2.63M-4.04M-6.06M
Investing Cash Flow
Financing Cash Flow

Harvard Apparatus Regenerative Technology Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.84
Price Trends
50DMA
1.61
Positive
100DMA
1.64
Positive
200DMA
2.06
Negative
Market Momentum
MACD
0.08
Negative
RSI
58.25
Neutral
STOCH
86.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Positive. The current price of 1.84 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.61, and below the 200-day MA of 2.06, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 86.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRGN.

Harvard Apparatus Regenerative Technology Risk Analysis

Harvard Apparatus Regenerative Technology disclosed 49 risk factors in its most recent earnings report. Harvard Apparatus Regenerative Technology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Harvard Apparatus Regenerative Technology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
109.80M-3.28-202.30%-28.23%93.42%
52
Neutral
520.01M-8.96-60.67%44.85%
48
Neutral
40.12M-0.25145.02%-3.49%27.88%
41
Neutral
35.91M-0.19239.23%-53.61%-93.14%
37
Underperform
$32.96M-2839.07%214.35%24.82%
34
Underperform
18.45M-0.2873.37%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HRGN
Harvard Apparatus Regenerative Technology
1.92
-3.61
-65.28%
LSTA
Lisata Therapeutics
2.36
-0.49
-17.19%
MBRX
Moleculin Biotech
0.42
-2.02
-82.79%
PULM
Pulmatrix
4.41
2.38
117.24%
SABS
SAB Biotherapeutics
2.10
-0.57
-21.35%
LGVN
Longeveron
0.79
-1.18
-59.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 18, 2024